In last trading session, Novavax, Inc. (NASDAQ:NVAX) saw 1,871,651 shares changing hands with its beta currently measuring 1.44. Company’s recent per share price level of $202.09 trading at $0.75 or 0.37% at ring of the bell on the day assigns it a market valuation of $14.93 Billion. That closing price of NVAX’s stock is at a discount of -64.12% from its 52-week high price of $331.68 and is indicating a premium of 92.88% from its 52-week low price of $14.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.3 Million shares which gives us an average trading volume of 4.47 Million if we extend that period to 3-months.
For Novavax, Inc. (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 5 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 5 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$2.65 in the current quarter.
Novavax, Inc. (NASDAQ:NVAX) trade information
Upright in the green during last session for gaining 0.37%, in the last five days NVAX remained trading in the green while hitting it’s week-highest on Wednesday, Apr 14 when the stock touched $211.54 price level, adding 4.47% to its value on the day. Novavax, Inc.’s shares saw a change of 81.23% in year-to-date performance and have moved 14.65% in past 5-day. Novavax, Inc. (NASDAQ:NVAX) showed a performance of -7.07% in past 30-days. Number of shares sold short was 4.29 Million shares which calculate 0.96 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $323 to the stock, which implies a rise of 59.83% to its current value. Analysts have been projecting $285 as a low price target for the stock while placing it at a high target of $365. It follows that stock’s current price would jump +80.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of 41.03% for stock’s current value.
Novavax, Inc. (NVAX) estimates and forecasts
Statistics highlight that Novavax, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +72.31% of value to its shares in past 6 months, showing an annual growth rate of -448.69% while that of industry is 7.9. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -356.9% in the current quarter and calculating 930% increase in the next quarter. This year revenue growth is estimated to rise 754.8% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $291.87 Million for the same. And 4 analysts are in estimates of company making revenue of $819.82 Million in the next quarter that will end on June 01, 2021. Company posted $3.38 Million and $39.58 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 8542.9% while estimating it to be 1971.3% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 9.5% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -32% while estimates for its earnings growth in next 5 years are of 0%
Novavax, Inc. (NASDAQ:NVAX)’s Major holders
Insiders are in possession of 0.37% of company’s total shares while institution are holding 53.73% percent of that, with stock having share float percentage of 53.93%. Investors also watch the number of corporate investors in a company very closely, which is 473 institutions for Novavax, Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at NVAX for having 5.6 Million shares of worth $624.32 Million. And as of December 30, 2020, it was holding 7.58% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 5.13 Million shares on December 30, 2020. The number of shares represents firm’s hold over 6.94% of outstanding shares, having a total worth of $571.57 Million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 1794677 shares of worth $200.12 Million or 2.43% of the total outstanding shares. The later fund manager was in possession of 1.51 Million shares on December 30, 2020, making its stake of worth around $168.26 Million in the company or a holder of 2.04% of company’s stock.